Trial reportScientific reports2025
Safety and efficacy of one-dose nocturnal levetiracetam for the treatment of self-limited epilepsy with centrotemporal spikes: a randomized clinical trial.
Trial report in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Self-Limited Focal Epilepsies in Childhood: How Many and How to Treat.Pediatric reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Self-limited epilepsy with centrotemporal spikes (SeLECTS) is associated with infrequent seizures but may cause behavioral problems and require more acceptable and effective intervention options. We aimed to compare the efficacy, adherence and safety of different levetiracetam administration methods for SeLECTS. We conducted a prospective, open-label and non-inferiority study; 192 children with SeLECTS were randomized into three groups: Group A (65 patients) received 2/3 of the daily dose in the evening and 1/3 in the morning; Group B (62 patients) took a single night-time dose; and Group C (65 patients) received equal split doses twice daily. After 6- and 12-months of treatment, Groups A and B were non-inferior to Group C in terms of seizure control and electroencephalogram normalization rate. Group B required the lowest effective dose, while Group C had higher blood drug concentrations (P < 0.05). Group B had lower Conners Parent Symptom Questionnaire scores for conduct problems, psychosomatic problems and anxiety compared to Group C (P < 0.05). Groups A and B had higher levels of satisfaction and adherence than Group C (P < 0.05), with no difference in adverse events. Collectively, these results demonstrated that for SeLECTS patients, a night-time single administration of levetiracetam ensures efficacy and improves both medication adherence and satisfaction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.